The following video is part of our "Motley Fool Conversations" series, in which analyst John Reeves and advisor Dave Meier discuss topics across the investing world.
Dave and John consider the prospects of Pfizer over the next five years. They both find its dividend pretty attractive, but they also wonder about its long-term potential. The video concludes with Dave's call on the stock.
If you like Pfizer's yield but are also interested in other dividend-paying companies, The Motley Fool has compiled a special free report outlining our 11 top, dependable, dividend-paying stocks. It's called "Secure Your Future With 11 Rock-Solid Dividend Stocks." You can access your complimentary copy today at no cost! Just click here to discover the winners we've picked.
At the time thisarticle was published Dave Meier and John Reeves have no positions in the stocks mentioned above. The Motley Fool owns shares of Teva Pharmaceutical Industries.Motley Fool newsletter services recommendPfizer and Teva Pharmaceutical Industries. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.